BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression

Leukemia

Volumn 23, Issue 9, 2009, Pages 1622-1627

  Kobayashi, S ^a   Kimura, F ^a   Ikeda, T ^b   Osawa, Y ^a   Torikai, H ^c   Kobayashi, A ^a   Sato, K ^a   Motoyoshi, K ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

BCR ABL; C Jun; CCAAT enhancer binding protein (C EBP); Chronic myeloid leukemia (CML); Microarray

Indexed keywords

BCR ABL PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PIPERAZINE DERIVATIVE; PROTEIN C JUN; PROTEIN KINASE B; PYRIMIDINE DERIVATIVE;

ARTICLE; CELL DIFFERENTIATION; CYTOLOGY; DOWN REGULATION; DRUG ANTAGONISM; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; MYELOID LEUKEMIA; NEUTROPHIL; PATHOLOGY; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; DOWN-REGULATION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; NEUTROPHILS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-JUN; PYRIMIDINES;

EID: 70349326117     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.74     Document Type: Article

References (39)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
2. Goldman JM, Melo JV. Chronic myeloid leukemiaFadvances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
3. Primo D, Sanchez ML, Espinosa AB, Tabernero MD, Rasillo A, Sayagues JM et al. Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL and mBCR/ABL cases. Br J Haematol 2006; 132: 736-739.
4. al-Amin A, Lennartz K, Runde V, Seeber S, Opalka B, Kloke O. Frequency of clonal B lymphocytes in chronic myelogenous leukemia evaluated by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998; 104: 45-47.
5. MacKinney Jr AA, Clark SS, Borcherding W, Fizzotti M, Hong R. Simultaneous demonstration of the Philadelphia chromosome in T, B, and myeloid cells. Am J Hematol 1993; 44: 48-52.
6. Takahashi N, Miura I, Saitoh K, Miura AB. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998; 92: 4758-4763.
7. Cho EK, Heo DS, Seol JG, Seo EJ, Chi HS, Kim ES et al. Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. Br J Haematol 2000; 111: 216-222.
8. Nakajima H, Zhao R, Lund TC, Ward J, Dolan M, Hirsch B et al. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J Immunol 2002; 168: 643-650.
9. Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, Laird C et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 2001; 97: 720-728.
10. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 1999; 96: 12804-12809.
11. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
12. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48-58.
13. Perrotti D, Calabretta B. Translational regulation by the p210 BCR/ABL oncoprotein. Oncogene 2004; 23: 3222-3229.
14. Schuster C, Forster K, Dierks H, Elsasser A, Behre G, Simon N et al. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Blood 2003; 101: 655-663.
15. Tavor S, Park DJ, Gery S, Vuong PT, Gombart AF, Koeffler HP. Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem 2003; 278: 52651-52659.
16. Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996; 87: 307-317.
17. Hao SX, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 2000; 20: 1149-1161.
18. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 2001; 104: 21-32.
19. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004; 119: 431-443.
20. Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003; 102: 3569-3574.
21. Pellagatti A, Esoof N, Watkins F, Langford CF, Vetrie D, Campbell LJ et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol 2004; 125: 576-583.
22. Goerttler PS, Kreutz C, Donauer J, Faller D, Maiwald T, Marz E et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol 2005; 129: 138-150.
23. Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA. Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. Mol Cell Biol 1993; 13: 841-851.
24. Szabo E, Preis LH, Birrer MJ. Constitutive cJun expression induces partial macrophage differentiation in U-937 cells. Cell Growth Differ 1994; 5: 439-446.
25. Li J, King I, Sartorelli AC. Differentiation of WEHI-3B D+ myelomonocytic leukemia cells induced by ectopic expression of the protooncogene c-Jun. Cell Growth Differ 1994; 5: 743-751.
26. van Dam H, Duyndam M, Rottier R, Bosch A, de Vries-Smits L, Herrlich P et al. Heterodimer formation of cJun and ATF-2 is responsible for induction of c-Jun by the 243 amino acid adenovirus E1A protein. EMBO J 1993; 12: 479-487.
27. Arias J, Alberts AS, Brindle P, Claret FX, Smeal T, Karin M et al. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 1994; 370: 226-229.
28. Friedman AD. Transcriptional regulation of granulocyte and monocyte development. Oncogene 2002; 21: 3377-3390.
29. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2006; 34: 1480-1489.
30. Borregaard N, Sehested M, Nielsen BS, Sengelov H, Kjeldsen L. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood 1995; 85: 812-817.
31. Theilgaard-Monch K, Jacobsen LC, Borup R, Rasmussen T, Bjerregaard MD, Nielsen FC et al. The transcriptional program of terminal granulocytic differentiation. Blood 2005; 105: 1785-1796.
32. Rangatia J, Vangala RK, Treiber N, Zhang P, Radomska H, Tenen DG et al. Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment. Mol Cell Biol 2002; 22: 8681-8694.
33. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998; 18: 4301-4314.
34. Wang D, D'Costa J, Civin CI, Friedman AD. C/EBPalpha directs monocytic commitment of primary myeloid progenitors. Blood 2006; 108: 1223-1229.
35. Friedman AD. Transcriptional control of granulocyte and monocyte development. Oncogene 2007; 26: 6816-6828.
36. Hilberg F, Aguzzi A, Howells N, Wagner EF. c-jun is essential for normal mouse development and hepatogenesis. Nature 1993; 365: 179-181.
37. Wagner K, Zhang P, Rosenbauer F, Drescher B, Kobayashi S, Radomska HS et al. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci USA 2006; 103: 6338-6343.
38. Zhelev Z, Bakalova R, Ohba H, Ewis A, Ishikawa M, Shinohara Y et al. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study). FEBS Lett 2004; 570: 195-204.
39. Ohba H, Zhelev Z, Bakalova R, Ewis A, Omori T, Ishikawa M et al. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes. Cancer 2004; 101: 1390-1403.